Chemical formula: C₃₁H₄₄FN₈O₁₇PS Molecular mass: 882.227 g/mol
Tenofovir disoproxil and Emtricitabine is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)
Emtricitabine/tenofovir disoproxil combination is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.
Emtricitabine/tenofovir disoproxil combination is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)
Emtricitabine/tenofovir disoproxil combination is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Tenofovir disoproxil and Emtricitabine is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
